Literature DB >> 7754621

pTNM and residual tumor classifications: problems of assessment and prognostic significance.

P Hermanek1.   

Abstract

The anatomic extent of tumor (TNM, pTNM) and, in case of treatment, the residual tumor status following treatment (residual tumor, or R classification) are the strongest predictors for outcome of patients with gastrointestinal cancer. The results of the pTNM and the R classifications depend on the methods used. In particular, the pN classification correlates with the number of nodes examined. The findings of micrometastases or isolated tumor cells in bone marrow should be indicated, and such cases must be analyzed separately from other metastatic cases. The same applies to patients with positive cytology in ascites fluid or peritoneal washings without gross involvement of the peritoneum. For the R classification the additional descriptors (conv), for conventional methods used, and (soph), for sophisticated, are recommended to indicate the methods used for classification. In general, long-term survival can be expected only after R0 resection (resection without residual tumor). The observed 5-year survival after R0 resection is 15% to 40% for esophageal carcinoma, 40% to 75% for gastric carcinoma, and 55% to 60% for colorectal carcinoma; the respective figures for R1 and R2 resections are only about 5% each. In R1 and R2 cases prognosis is determined primarily by the absence or presence of distant metastases, and pT and pN are of minor significance. After R0 resection there is a wide spectrum of prognoses. Careful pTNM classification allows a good estimation of the prognosis and can be considered the gold standard for any analysis of treatment results.

Entities:  

Mesh:

Year:  1995        PMID: 7754621     DOI: 10.1007/BF00308624

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

1.  Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT).

Authors:  L P Fielding; P A Arsenault; P H Chapuis; O Dent; B Gathright; J D Hardcastle; P Hermanek; J R Jass; R C Newland
Journal:  J Gastroenterol Hepatol       Date:  1991 Jul-Aug       Impact factor: 4.029

2.  Guide lines for the clinical and pathologic studies on carcinoma of the esophagus.

Authors: 
Journal:  Jpn J Surg       Date:  1976-06

3.  The relationship between surgeons and pathologists in treating cancer.

Authors:  P Hermanek
Journal:  Eur J Surg Oncol       Date:  1987-04       Impact factor: 4.424

Review 4.  Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer.

Authors:  C M Fenoglio-Preiser
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

5.  Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group.

Authors:  J R Siewert; K Böttcher; J D Roder; R Busch; P Hermanek; H J Meyer
Journal:  Br J Surg       Date:  1993-08       Impact factor: 6.939

6.  [Importance of tumor growth and spread for surgical radical excision].

Authors:  C Wittekind
Journal:  Zentralbl Chir       Date:  1993       Impact factor: 0.942

7.  [Oncologic surgery/pathologic-anatomic viewpoint].

Authors:  P Hermanek
Journal:  Langenbecks Arch Chir Suppl Kongressbd       Date:  1991

8.  Implications of peritoneal cytology for staging of early pancreatic cancer.

Authors:  A L Warshaw
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

9.  Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer--can monoclonal antibodies do better?

Authors:  N S Ambrose; F MacDonald; J Young; H Thompson; M R Keighley
Journal:  Eur J Surg Oncol       Date:  1989-04       Impact factor: 4.424

10.  [Systematic extended lymph node dissection in curative therapy of stomach cancer].

Authors:  F P Gall; P Hermanek
Journal:  Chirurg       Date:  1993-12       Impact factor: 0.955

View more
  26 in total

1.  Superiority of metastatic lymph node ratio to the 7th edition UICC N staging in gastric cancer.

Authors:  Long-Bin Xiao; Jian-Xing Yu; Wen-Hui Wu; Feng-Feng Xu; Shi-Bin Yang
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

2.  [The cytological demonstration of micrometastases in the bone marrow].

Authors:  J Dunst
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

3.  Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma.

Authors:  Christophe Mariette; Laetitia Finzi; Guillaume Piessen; Isabelle Van Seuningen; Jean Pierre Triboulet
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

4.  Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells.

Authors:  J M Silva; R Rodriguez; J M Garcia; C Muñoz; J Silva; G Dominguez; M Provencio; P España; F Bonilla
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

5.  Multiple localized metachronous recurrences in a patient of colon cancer and therapeutic controversies in stage II colon cancer.

Authors:  Vijai Simha; Rakesh Kapoor; Saniya Sharma
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-18

6.  Ultrastaging of colon cancer by sentinel node biopsy using fluorescence navigation with indocyanine green.

Authors:  Christoph Hirche; Zarah Mohr; Sören Kneif; Sergiu Doniga; Dawid Murawa; Martin Strik; Michael Hünerbein
Journal:  Int J Colorectal Dis       Date:  2011-09-13       Impact factor: 2.571

Review 7.  [Pathology of the R1 classification in visceral cancer surgery].

Authors:  M J Pollheimer; C Langner
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

8.  Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study.

Authors:  J R Siewert; K Böttcher; H J Stein; J D Roder
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

9.  Clinical Significance of the Pre-therapeutic Nodal Size in Patients Undergoing Neo-Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma.

Authors:  Shinji Mine; Masayuki Watanabe; Yu Imamura; Akihiko Okamura; Takanori Kurogochi; Takeshi Sano
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

10.  Prognostic value of microvascular density in dukes a and B (t1-t4, n0, m0) colorectal carcinomas.

Authors:  Rafael Uribarrena A; Javier Ortego; Javier Fuentes; Nuria Raventós; Pilar Parra; Rafael Uribarrena E
Journal:  Gastroenterol Res Pract       Date:  2009-11-04       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.